Elo Mutual Pension Insurance Co Buys 3,746 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Elo Mutual Pension Insurance Co increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.5% during the 4th quarter, Holdings Channel reports. The fund owned 22,020 shares of the medical equipment provider’s stock after acquiring an additional 3,746 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Zimmer Biomet were worth $2,326,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth about $25,000. Dunhill Financial LLC boosted its holdings in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Brooklyn Investment Group acquired a new stake in Zimmer Biomet in the third quarter valued at approximately $35,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $39,000. Finally, OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet during the fourth quarter worth approximately $40,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.95% of the stock is currently owned by insiders.

Zimmer Biomet Trading Up 0.1 %

Shares of ZBH opened at $112.21 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $131.61. The business has a 50-day moving average of $107.18 and a 200 day moving average of $107.02. The firm has a market cap of $22.34 billion, a P/E ratio of 25.22, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company earned $2.20 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Truist Financial reissued a “hold” rating and issued a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. JMP Securities reissued a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Stifel Nicolaus lifted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.